RYTM
NASDAQ
$106.60
Rhythm Pharmaceuticals Inc (RYTM)
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $139.73 (+31.08%)
Market Cap
$7.51B
Revenue 5Y CAGR
+473.51%
Free Cash Flow Yield
-1.60%
Beta (5Y)
0.88
Price Chart
Valuation
Market Cap$7.51B
P/S34.39
P/B61.37
Profitability
Total Revenue (TTM)$217M
Gross Profit (TTM)$194M
EBITDA-$198M
Profit Margin-92.6%
Operating Margin-87.1%
EPS-$3.04
Financial Health
Debt-to-Equity88.3%
Free Cash Flow Yield-1.60%
Growth & Risk
EPS 5Y CAGR+17.00%
Revenue 5Y CAGR+473.51%
FCF 5Y CAGR+0.14%
Beta (5Y)0.88
Sharpe Ratio0.46